ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …
…, VV McLaughlin, SL Archer, DB Badesch… - Circulation, 2009 - Am Heart Assoc
Pulmonary hypertension (PH) is a complex, multidisciplinary disorder. Recent advances
have led to increased recognition and new therapies. While some data exist to form …
have led to increased recognition and new therapies. While some data exist to form …
Definitions and diagnosis of pulmonary hypertension
…, T Satoh, F Torres, MR Wilkins, DB Badesch - Journal of the American …, 2013 - jacc.org
… Badesch has received grant funding from Actelion/CoTherix, Gilead, Pfizer, United
Therapeutics/Lung Rx, Eli Lilly/ICOS, Bayer, Novartis, Ikaria, and ARIES ; has served as a consultant (…
Therapeutics/Lung Rx, Eli Lilly/ICOS, Bayer, Novartis, Ikaria, and ARIES ; has served as a consultant (…
Diagnosis and assessment of pulmonary arterial hypertension
DB Badesch, HC Champion… - Journal of the American …, 2009 - jacc.org
… Badesch has received honoraria for service on steering committees and advisory boards
from Actelion (CoTherix), Biogen IDEC, Encysive, Gilead (Myogen), GlaxoSmithKline, Lilly, …
from Actelion (CoTherix), Biogen IDEC, Encysive, Gilead (Myogen), GlaxoSmithKline, Lilly, …
[HTML][HTML] Bosentan therapy for pulmonary arterial hypertension
Background Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a
preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved …
preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved …
[HTML][HTML] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
…, MD McGoon, S Rich, DB Badesch… - … England Journal of …, 1996 - Mass Medical Soc
Background Primary pulmonary hypertension is a progressive disease for which no treatment
has been shown in a prospective, randomized trial to improve survival. Methods We …
has been shown in a prospective, randomized trial to improve survival. Methods We …
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
…, IM Robbins, A Frost, VF Tapson, DB Badesch… - The Lancet, 2001 - thelancet.com
Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management …
…, CS Coffey, A Frost, RJ Barst, DB Badesch… - Circulation, 2010 - Am Heart Assoc
… Among all patients, there are some hypothesized predictors that were not captured in our
database such as tricuspid annular plane systolic excursion, serum sodium levels, and …
database such as tricuspid annular plane systolic excursion, serum sodium levels, and …
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial
DB Badesch, VF Tapson, MD McGoon… - Annals of internal …, 2000 - acpjournals.org
Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …
scleroderma spectrum of disease for which no treatment has been proven effective in a …
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
DB Badesch, GE Raskob, CG Elliott, AM Krichman… - Chest, 2010 - Elsevier
… Financial/nonfinancial disclosures: The authors have reported to CHEST the following
conflicts of interest: Dr Badesch has served as a consultant for Actelion/CoTherix, Gilead/Myogen, …
conflicts of interest: Dr Badesch has served as a consultant for Actelion/CoTherix, Gilead/Myogen, …
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo …
…, F Torres, A Frost, HA Ghofrani, DB Badesch… - Circulation, 2008 - Am Heart Assoc
… Dr Badesch has served on the advisory boards of Gilead, Actelion, Pfizer, Encysive, GSK,
and United Therapeutics. He has received lecture fees from Gilead and Actelion; honoraria …
and United Therapeutics. He has received lecture fees from Gilead and Actelion; honoraria …